Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues

Godman, B. ✉; Tubic, B.; Allocati, E.; Wladysiuk, M.; McTaggart, S.; Kurdi, A.; Haque, M.; MacBride-Stewart, S.; Kalemeera, F.; Massele, A.; Hoxha, I.; Pekovic, V.M.; Petrova, G.; Tachkov, K.; Laius, O.; Harsanyi, A.; Inotai, A. [Inotai, András (farmakoökonómia), author] Center for Health Technology Assessment (SU / KSZE); Jakupi, A.; Henkuzens, S.; Garuolienė, K.; Bonanno, P.V.; Rutkowski, J.; Mardare, I.; Fürst, J.; Pontes, C.; Zara, C.; Pedrola, M.T.; Akter, F.; Kwon, H.-Y.; Martin, A.P.; Banzi, R.; Wale, J.; Gulbinovič, J.